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Abstract 
Introduction: Breast cancer accounts for 29% of malignant tumors. It is an heterogenous disease 
covering a spectrum of different molecular subtypes. Epigenetic aberrations may affect gene 
expression through DNA and histone proteins modifications thus promoting tumor progression and 
resistance to anti- tumor treatment.  
Area covered: This article explores the potential role of entinostat in the treatment of breast cancer. 
The clinical trials evaluating entinostat are discussed, highlighting preclinical data and early-phase 
clinical studies results. The emerging activity of entinostat in several clinical settings is evaluated by 
focusing on endocrine-resistant, HER2 positive and triple-negative breast cancer with a promising 
activity as an immune-system boosting. 
Expert opinion: Entinostat, a synthetic benzamide derivative class I histone deacetylases (HDACs) 
inhibitor, inhibits cell proliferation and promotes apoptosis in breast cancer. Several results from 
clinical trials demonstrate that the addition of an epigenetic therapy to antiestrogen therapy may 
be an effective approach to targeting resistance pathways in breast cancer, particularly in hormone-
positive disease. Agents as entinostat may have a role in immunogenic modulation. Genetic and 
pharmacological inhibition studies identified HDAC  as a key determinant in the reversal of 
carcinoma immune escape. This offers the rationale for combining HDAC inhibitors with 
immunotherapy, including therapeutic cancer vaccines. 
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1. Introduction  
Breast cancer is the mostly diagnosed cancer in women with 249,260 new cases expected for 2016: 
it accounts for 29% malignant tumors in women with a lifelong risk of 12.5% (1). Breast cancer is an 
heterogeneous disease covering a spectrum of subtypes with several histological and molecular 
features affecting prognosis (2). The comprehensive molecular “portrait” of breast cancer reveals 
four tumor subtypes: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)- 
overexpressing and basal-like tumors (2), each one characterized by specific genetic and epigenetic 
abnormalities. Interestingly, these molecular defined subgroups may recapitulate the four main 
breast cancer intrinsic subtypes as defined in clinical practice through immunohistochemistry assays 
based on estrogen (ER) and progesterone receptor (PgR), together with HER2- testing and ki-67 as 
index of proliferation (3, 4).  
Overview of the epigenetic landscapes of cancer   
The mechanisms of resistance in breast cancer is the result of a clonal evolution. Furthermore, 
genome instability and intratumor heterogeneity contributes to drug resistance and may promote 
the selection of resistant subclones, each one with a specific enabling mutant genotype (5). Genomic 
instability affects the mutational rate of the tumor through several defects: DNA base and 
nucleotide excision and mismatch repair, telomere maintenance, double-strand break repair, DNA 
replication, chromosome segregation (6). The differential gene expression can be related to both 
genetic and epigenetic mechanisms. As a result tumor heterogeneity can be influenced by non-
mutational changes affecting gene expression or, properly, by epigenetic mechanisms. These 
modifications can alter the DNA primary sequence and chromatin compacting regulation through 
nucleotide or nucleosome-protein modifications. Indeed, each tumor is characterized by a particular 
epigenetic profile. Neoplastic cells can display different profiles of nucleotidic methylation on 
cyosine- guanosine (CpG) rich regions (CpG islands): a hypo-methylated profile is associated with 
chromosomal instability thus impacting on tumor mutagenic rate and outcome (7). Conversely, 
hyper- methylation of CpG islands on gene promoter regions leads mostly to gene silencing (8). In 
addition, expression of tumor suppressor or activating genes can be regulated by post- translational 
modification of histone proteins such as methylation, acetylation, phosphorylation, ubiquitylation, 
sumoylation. Histone modifications have been observed in arginine, lysine and serine residues of 
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histone proteins (9). Histone-tails modifying enzymes govern these post-translational modifications: 
histone acetyltransferases (HATs), histone methyltransferases (HMTs), histone deacetylases 
(HDACs) and histone demethylase (HDMTs). As a general rule, histone acetylation leads to 
transcriptional activation.  Specifically, HDACs are collected in 3 class according to the homology 
with yeast homologous genes. Class I, in particular, comprises HDAC 1, 2, 3 and 8, representing the 
homologous genes to yeast protein RPD3 (10). The acetylation of lysine residues on histone tails 
neutralizes the positive charge of the ε-amino groups, which is the determinant of the interaction 
of histone proteins to DNA by binding to the negatively charged phosphodiester backbone, thus 
influencing the condensation state of DNA. Therefore, a different state of chromatin compaction 
can allow the access to transcription factors thus enhancing gene expression (Figure 1).  Moreover, 
acetylated lysine can bind reader proteins through acetylated- lysine recognition domain (i.e. 
bromodomain) thus recruiting diverse nuclear proteins including chromatin remodeling complex 
proteins and co-activators of transcription. (11). HDACs remove the acetyl group from the histone 
tail thus enabling the chromatin to condense and restrict access of bromodomain- containing 
proteins  to the DNA, resulting in gene expression negative regulation. Inhibition of HDAC enzymes 
affect cellular proliferation through the repression of key genes involved in cell-cycle progression, 
functioning as a cell growth inhibitor. One of the most extensively studied is the cyclin-dependent 
kinase (CDK) inhibitor CDKN1A / p21WAF1 (CIP1) that has been showed to be increased in cancer cell 
lines treated with different HDAC- inhibitors (12).  Taken together, the possibility to reverse the 
epigenetic aberrations that cause chemoresistance and impaired response to targeted therapy of 
tumor cells is called “episensitization”: this possibility of resistance-reversal is attractive as it is 
amenable to pharmacologic control (13). Interestingly, in-vitro experience with  breast cell lines 
showed an “epigenetic profile” of HDACs expression and mutation. Particularly, an overexpression 
of HDAC1 has been described in breast and gastric malignant neoplasms (10).  This may offer the 
rationale to target differentially HDAC isoforms  as an attempt to target more precisely the different 
histologically- and molecularly- defined tumors.  
  
 
 
 
2. Chemistry and pharmacology of entinostat 
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2.1 Pharmacodynamics. Entinostat (MS-275) is an oral synthetic benzamide-derivative capable to 
inhibit HDAC1 and 3 enzymes. Preliminary data showed the potential antiproliferative activity of 
entinostat in several cell line, including breast cancer in-vitro and in-vivo xenograft models (14). 
Translational experiences showed that tumor growth suppression requires 3-4 weeks of exposure 
to entinostat; this is in accordance with the unique mechanism of action of this drug that targets a 
general thus finely regulated mechanism of gene expression in order to rescue an anti-proliferative 
expression pattern (15).   
 
2.2 Pharmacokinetics. Pharmacokinetic studies revealed a maximum plasma levels of entinostat 
reached within 1 h after a single dose administration and a terminal half-life value estimated  
between 60 and 150 h with a t-max equal to 1h (16).  
2.3 Metabolism. A renal and biliary clearance of entinostat using a radiolabeled model in baboons 
and cancer patients model has been studied; a possible entero-hepatic recirculation has been supposed 
(17). However, liver metabolism seems to be a minor pathway of drug elimination in humans, as showed by 
Ryan et al. (16). 
 
3. Safety and tolerability 
The safety profile of entinostat is favorable; most frequent grade 3 and 4 adverse events are 
hematological such as thrombocytopenia (63%), anemia (47%), neutropenia (41%), leukopenia 
(10%) and non- hematological like hypokalemia (8%), and hypophosphatemia (6%) unrelated to 
nephrotoxicity (18).  
4. Preclinical and clinical experiences for breast cancer treatment 
4.1 Hormone receptor positive breast cancer 
Up to 70% of breast cancer are ER positive at diagnosis; ER-positive breast cancers at initial 
diagnosis, however, can lose ER- expression, showing different grades of endocrine therapy 
resistance (19). ER-α repression is often related to an epigenetic aberration. When treated with 
entinostat, ER-negative breast cancer cells show an increasing response to endocrine treatment 
with aromatase inhibitors in a dose dependent manner, so re-sensitizing tumor cells to endocrine 
therapy (20).  Histone modifying enzymes can mediate endocrine-resistance of breast cancer 
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through co-repressor proteins. Tamoxifen is an ER modulator capable of inducing a conformational 
change of ER that favors the recruitment of co-repressors (21). These proteins can interact with 
HDAC and mediate a trans-repression of ER- related genes. Accordingly, loss of ER- corepressors, 
due mainly to mutational events or deletion, may affect the response of tumor to endocrine- 
treatment, altering the compaction of chromatin; again, this same mechanism can predispose cells 
to the antitumor effect of HDAC- inhibitors (22).   Yardley et al. (23) published a phase 2 study 
(ENCORE 301) of exemestane and entinostat for the treatment of ER-positive breast cancer 
progressing on treatment with a nonsteroidal aromatase inhibitor. The schedule adopted was 
entinostat 5 mg PO weekly continued until progressive disease (PD) or unacceptable toxicity. They showed 
a drug activity for the combination arm in term of progression free survival -PFS (HR=0.73, p=0.055) 
and OS (median increase of +8.29 months). Interestingly, ENCORE 301 pharmacodynamics analysis 
found a predictive role for the hyper-acetylation DNA profile as showed on circulating lymphocytes 
on liquid biopsy samples: “high acetylators” patients had a better PFS,  as found in peripheral blood 
monocytes, B- and T- lymphocytes with a multiparameter flow cytometry assay (HR=0.32-0.50). The 
threshold to define the “acetylator” profile was defined as the percent change in protein lysine 
acetylation at cycle 1 day 15 versus the study derived median value. Thus, a role in endocrine- 
resistance is conceivable with a potential incorporation of entinostat in endocrine- resistant breast 
cancer treatment in a similar position as CDK4/6 inhibitors, PI3K/mTOR and AKT/PTEN blockers (24). 
An ongoing phase3 trial (25), sponsored by the national cancer institute (NCI), will be decisional for 
the inclusion of entinostat in the armamentarium of this clinical scenario (Table 1). 
 
4.2 HER2- overexpressing breast cancer 
About 25% of breast cancer overexpress HER2 oncoprotein and are associated with a worse 
prognosis than HER2- negative/ER-positive tumors not treated with a targeted therapy (26).  At now, 
anti-HER2 treatment with monoclonal antibodies (i.e. trastuzumab, pertuzumab, TDM-1) and small 
molecules (lapatinib) are approved in different clinical settings with a significant improvement of 
the outcome compared to chemotherapy alone. However, resistances to HER2-inhibitors frequently 
occur, and resistance- crossing strategies are needed (27). The majority of patients under treatment 
with trastuzumab, despite an initial response, may develop a drug resistance within one year (28).  
Anti-HER2 treatment resistance can be mediated by the activation of counter-regulatory pathways 
such as the formation of heterotrimeric complex of HER2 with both HER3 and the insulin-like growth 
factor-1 (IGF1) or the activation of the PI3K-Akt-mTOR pathway (29).  Huang et al reported an 
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enhancing activity of entinostat when combined with trastuzumab in HER2-overexpressing breast 
cancer. Particularly, entinostat exhibited a downregulating effect on HER2 and HER3 with a dramatic 
inactivation of phosphoinositide 3-kinase (PI3K)/Akt signaling, thus disrupting the two main 
mechanisms of cancer resistance to trastuzumab treatment (30). Moreover, this activity was 
confirmed in a trastuzumab- resistant cancer model in which the association of trastuzumab and 
entinostat exhibited a repressive activity on tumor growth with a substantial enhancement of 
apoptosis (31).   Similarly, Lee J et al (32) reported a synergistic activity of entinostat when combined 
to lapatinib with a significant in vivo tumor shrinkage. This antitumor activity was showed to be 
mediated by a downregulation of phosphorylated Akt and activation of the pro-apoptotic protein 
Bim1. Moreover, when incorporated in a double- blockade regiment with lapatinib and 
trastuzumab, the antiproliferative effect of entinostat resulted to be improved in comparison with 
the single anti-HER2 regimen. Based on these results, a phase 1 study is ongoing for trastuzumab- 
resistant HER2-positive breast cancer (33): preliminary results of entinostat and lapatinib with or 
without trastuzumab showed that the triplet is feasible, safe and effective (34).  
4.3 Triple negative breast cancer  
Triple negative breast cancer subtype (TNBC) encompasses a heterogeneous group of breast 
malignancies defined by the lack of expression of ER, PgR and HER2. TNBC accounts for almost 15% 
of breast malignancies and it is associated with an intrinsic biological aggressiveness and generally 
with a worse prognosis. At least, six distinct molecular subtypes have been described by Lehmann 
et al (35), differently associated with outcome and response to neoadjuvant chemotherapy (36). 
However, no target therapy has been so far approved for TNBC and the treatment of choice remains 
the cytotoxic chemotherapy.  Basal- like subtype of TNBC is characterized by a loss of the expression 
of E-cadherin and a transition into a mesenchymal- type cell with increasing expression of N- 
cadherin and vimentin; this process can properly be named “epithelial to mesenchymal transition” 
(EMT). Specific cell features of EMT are loss of intracellular adhesion molecules, acquisition of 
spindle fibroblast-like morphology and motility thus acquiring a phenotype suitable for 
metastatizing (37). However, mutations in CDH1 gene, encoding for E-cadherin, are rare and the 
main mechanism of E-cadherin gene regulation seems to be an epigenetic silencing (38). Cells that 
activate EMT, seems to acquire the features of tumor initiating cells (TICs), characterized by their 
ability to reseed a tumor even when few cells are inoculated (39).  Shah et al (40) showed a reversal 
of EMT phenotype in a cell model of basal like TNBC exposed to  entinostat with a rescue of E-
cadherin expression: migration inhibition and cell morphology change was reported together with 
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a reduced potential to metastatize.  Additionally, entinostat was able to reprogram the TIC 
phenotype in a basal- like TNBC cellular model: when exposed to entinostat, TNBC cells showed a 
normalization of CD44/CD24 surface expression together with a growth control of the primary 
tumor and a reduction of the ability of TNBC cancer cells to colonize distant sites (41).  Merino et al 
reported an ex-vivo animal model of combination therapy of entinostat with a differentiating agent 
(all-trans retinoic acid, ATRA) and doxorubicin (42). In particular, entinostat was able to reverse 
retinoid acid receptor (RAR-β) epigenetic silencing thus enhancing cell drug sensitivity to ATRA. 
Additionally, entinostat appeared to reduce topoisomerase II-α and II-β expression, defining a 
synergistic mechanism of action with doxorubicin.  According to these preclinical evidences, a phase 
1 trial for solid tumors was published by Pili et al (43) with entinostat plus 13-cis retinoic acid; a 
preliminary evidence of  prolonged stable disease was reported in heavenly pretreated patients with 
prostate, pancreatic and kidney cancer (43).  
4.4 Immune- regulating activity for breast cancer immunotherapy 
The key assumption founding the rational basis for cancer immunotherapy is the concept of 
immune-surveillance. Immune system, indeed, can suppress the development of cancer clones thus 
offering an endogenous anti-cancer activity (44, 45). The growing success of the “stimulus and co-
stimulus axis” immune-checkpoint regulators have led to clinically validated treatments for a wide 
spectrum of neoplastic disease; truly, cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and 
programmed cell death protein 1 (PD1) ligand 1 (PDL-1)  blocking monoclonal antibodies have 
defined a new era of immunotherapy for nearly all types of cancer. When treated with a HDAC 
inhibitor, breast cancer cells show to be more sensitive to the killing activity of cytotoxic T-
lymphocytes (CTL) (46). In particular, HDAC 1 inhibition enhances the antigen- mediated cancer cell 
killing through a HLA- restricted mechanism. Also, HDAC1 is involved in the epigenetic regulation of 
genes that participates to the antigen recognition process and co-repressors regulation (47). 
Moreover, HDAC influences chemokine tumor expression and is capable of interfering with anti-
cancer immune response to immune checkpoint inhibitors like PD-1 blockers, resulting in a brisker 
T-cell intratumor infiltration and T-cell–dependent tumor regression (48). Furthermore, HDAC 
inhibition results in an up-regulation of PDL-1, showing that HDAC-inhibitors may synergistically 
boost anti- PD1/PD-L1 drugs activity (48). In an immune subset analysis from the previously cited 
ENCORE 301 trial (25), entinostat was confirmed to produce immunomodulatory effects in a cohort 
of ER- positive breast cancer patients (50). Particularly, an increase of HLA- DR-positive monocytes 
was observed together with a significant reduction in granulocytic and monocytic myeloid- derived 
9 
 
suppressor cells. Taken together, these data show an immune-stimulating switch of the association 
therapy with exemestane and entinostat, hence providing a rationale for immune- checkpoint 
inhibitor association to endocrine therapy and HDAC- modulators (Table2).  
5. Competitor drugs in development 
Clinical drug development of entinostat is focusing on breast cancer resistance mechanisms to 
endocrine therapy and to HER2-targeting agents. Therefore, clinical competitors are being 
developing contemporary in diverse clinical settings. Endocrine resistance in breast cancer involves 
different pathways of interest: ER-alpha expression levels, up-regulation of growth factors signaling 
pathways (HER2, IGFR1, and FGFR1), downstream activation of the mitogen-activated protein 
kinase (MAPK) or PI3K cascade, CDK4/6, and let-7 miRNA family dysregulation (51). Similarly, 
trastuzumab resistance can be determined by several aberrations that interest PI3K/ mTOR 
pathway, cell- cycle control, IGFR1, MAPK (52). For at least each of these anomalies, a drug is under 
clinical evaluation and some of them are reaching a definite position in clinical field within few 
months.  
6. Expert opinion.   
Entinostat is a promising drug under development for the treatment of breast cancer in different 
clinical settings. Its unique mechanism of action interferes with a general mechanism of 
tumorigenesis, involving several and different oncogenic pathways that promote and sustain tumor 
progression. Conversely, entinostat targets class I HDACs (HDAC 1 and 3) so defining a tailored 
mechanism of action with a specific antitumor activity, too. In particular, entinostat can be 
combined with targeted- therapy as a booster of clinical activity as well as in association with 
immune-targeting treatments in support of a stronger antitumor immunity response and 
incorporated in chemotherapy regimens with potential synergistic activity. In addition, entinostat 
has a long half- life and can be administered once weekly PO, making this medication unique 
compared with other HDAC “broad spectrum” modulators such as azacitidine. Even though long 
term side effects are not completely known, Entinostat may be used for long term and beyond 
progression of disease –even if contrasting data exists (58)-  expecting a persistent antitumor effect: 
this class of epigenetic- modulator drugs may create a favorable genomic profile prone to a pro-
apoptotic and immune- activating context that may act in a promiscuous manner with several 
combined and sequential partner-drugs. Furthermore, patients may be monitoring before, during 
and at progression with liquid biopsy to detect a peculiar epigenetic profile predictive of response 
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to entinostat on circulating cancer cells and immune- competent cells or identify emerging mutation 
or epigenetic aberration of resistance to HDAC modifiers. Moreover, some of this epigenetic 
changes (i.e. cycle 1 day 15 lysine acetylation change) may be an early predictor of response to 
entinostat. However, further prospective data on endocrine resistance reversal, long term toxicity 
and immune- related adverse events enhancing are still needed. In an optimistic scenario, entinostat 
will be a promiscuous and transversal drug to be prescribed for almost all breast cancer subtypes as 
well as in several clinical setting as a general booster of antitumor activity.  
 
  
  
 
 
 
 
 
 
 
 
 
 
Table 1. Synoptic table of entinostat 
 
 
Drug name (company name) Entinostat  (Syndax Pharmaceuticals, Inc., 
Waltham, MA) 
Other names: SNDX-275, MS-275 
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Phase  1, 2 and 3, ongoing  
Indication   Hodgkin’s lymphoma, leukemia, lung cancer, 
breast cancer, melanoma, ovarian cancer  
Route of administration  Oral  
Chemical structure  C21H20N4O3  
Pyridylmethyl-N-{4-[(2-aminophenyl)-
carbamoyl]-benzyl}-carbamate 
Pivotal trials ongoing: Ref 22, 24, 32, 33, 52, 53, 54, 55, 56 
 
Table 2. Ongoing trials with entinostat for the treatment of breast cancer 
 
Partner- Drug Phase  Disease   Setting  ClinicalTrials.gov 
identifier 
Exemestane   
Goserelin 
III HRBC LABC/M   NCT02115282 
Anastrozole  II TNBC Neoadjuvant  NCT01234532 
Nivolumab 
Ipilimumab 
I HER2-
negative Breast Cancer 
 
LABC/M   NCT02453620 
Azacitidine II HRBC, TNBC, HER2-positive  LABC/M   NCT01349959 
Exemestane   I HRBC LABC/M* NCT02833155 
Atezolizumab Ib TNBC LABC/M NCT02708680 
Pembrolizumab I HRBC, TNBC, HER2-positive LABC/M NCT02909452 
Trastuzumab 
Lapatinib  
I HER2- positive LABC/M NCT01434303 
BC, breast cancer. HRBC, estrogen and/or progesterone receptor- positive BC. TNBC, triple negative 
BC. HER2, human epidermal growth factor receptor 2. LABC/M, locally advanced or metastatic 
breast cancer (palliative setting). *Only Chinese postmenopausal patients (Last update October 
2016).  
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Figure 1. Epigenetics modifications are involved in endocrine-resistance of breast cancer 
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The acetylation of lysine residues on histone tails determines a different state of chromatin 
condensation thus allowing access to transcription factors and possibly, but not only, enhancing 
gene expression. Aberrations in the acetylation pattern of cancer cells DNA can repress the 
expression of estrogen receptor (A) as one of mechanism leading to antitumor activity. When 
treated with entinostat (B), endocrine- resistant breast cancer cells show an increasing response to 
the treatment with exemestane, displaying a re-sensitization to aromatase inhibitors. Similar 
regulatory mechanisms of gene expression are involved in the re- sensitization to trastuzumab in 
breast cancer progressing to anti-HER2 treatment as well as in the immune- modulatory effects of 
entinostat (see the text for more details). HDAC, Histone deacetylase 1 and 3. ENT, Entinostat. ER, 
oestrogen receptor.  
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